A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.-MedSci.cn

A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.

Einstein, DJ; Choudhury, AD; Saylor, PJ; Werner, L; Erlander, MG; Ridinger, M; Bubley, G

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (7):

科室
- - 订阅+
  - 更多科室
工具
服务